Specialised Therapeutics Alim Pty Ltd

Regulatory activities for this sponsor.

Filters applied:

Prescription medicine decision summary

2 result(s) found, displaying 1 to 2

Minjuvi

3 July 2023

Prescription medicine decision summary

We have approved Minjuvi (tafasitamab) to treat diffuse large B-cell lymphoma (DLBCL).
Pemazyre

27 September 2022

Prescription medicine decision summary

TGA decision: Pemazyre (pemigatinib) is approved to treat cancer